Skip Navigation

Nephrology Dialysis Transplantation 2005 20(Supplement 8):viii13-viii17; doi:10.1093/ndt/gfh1111
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Portolés, J.
Right arrow Articles by de Francisco, A. L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Portolés, J.
Right arrow Articles by de Francisco, A. L. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

Exploring dosing frequency and administration routes in the treatment of anaemia in CKD patients

Jose Portolés1, Peter Krisper2, Gabriel Choukroun3 and Angel L. M. de Francisco4

1 Nephrology Unit, Fundación Hospital Alcorcón, Madrid, 2 Abteilung für Nephrologie und Haemodialyse, Medizinische Universitaetsklinik Graz, Austria, 3 Néphrologie et Médecine Interne, CHU d'Amiens, Hôpital Sud, Amiens, France and 4 Nephrology Service, Hospital Universitario de Valdecilla, Cantabria, Spain

Correspondence and offprint requests to: Jose Portolés MD, PhD, Head of Nephrology Unit, Fundación Hospital Alcorcón, Avda villaviciosa s.n. Alcorcón, 28922 Madrid, Spain. Email: jmportoles{at}fhalcorcon.es

Erythropoiesis-stimulating agents have dramatically changed the management of renal anaemia since their introduction almost 20 years ago. However, optimal dosing route and frequency are still a matter of debate. Intravenous application of recombinant human erythropoietin should be limited to haemodialysis patients and must be given three times weekly, as any reduction to this dosing frequency leads to a major increase in dose requirements. Administering recombinant human erythropoietin-ß once weekly via the subcutaneous route is effective. If conversion from the subcutaneous to the intravenous route is required, dose requirements for recombinant human erythropoietin therapy remain a subject of discussion.

Keywords: chronic kidney disease; doses and routes; erythropoietin; renal anaemia


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.